# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mary McLeod Bethune (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML043-SYN-TD
- Date: 1948-07-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Viola Harrington-Mbeki, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Asthma review six weeks after an exacerbation. **S**

## History of present illness

Mrs. Bethune returns six weeks after the moderate exacerbation that followed a cold, treated at the sick visit with extra budesonide-formoterol, five days of prednisone and a step-up to two maintenance inhalations twice daily. The clinic nurse telephoned her two and seven days later and she was recovering, but she was not seen in person within the week. Since then she has had no night waking and uses the reliever about once a week; she has been to two board meetings in Washington without breathlessness. Her peak flow has been 320 to 345 L/min each morning. She uses the spacer each time and has missed only a few doses. She stopped omeprazole as planned and has had heartburn only once. Home blood pressure averages 126/76. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Exacerbation | Moderate, with a cold, six weeks ago; prednisone for five days; no emergency visit |
| Since then | No night waking; reliever about once a week; peak flow 320 to 345 L/min |
| Travel | Two meetings in Washington without breathlessness |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No night waking or breathlessness on stairs |
| Ears, nose, mouth, and throat | Negative | Nose clear; no hoarseness or thrush |
| Gastrointestinal | Negative | Heartburn once since stopping omeprazole |
| Cardiovascular | Negative | No ankle swelling or chest pain |
| Psychiatric | Negative | Mood good; PHQ-2 0 |

5 systems reviewed. **S**

## Current medications

- Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: one inhalation twice daily and one as needed, no more than 12 inhalations a day **S**
- Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum **S**
- Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.5 °C; oxygen saturation 97% on room air; weight 86.4 kg; BMI 32.5 kg/m². All vital signs are synthetic.

Asthma Control Test: 22; FEV1 before bronchodilator: 1.72 L; FEV1 percent predicted before bronchodilator: 85%; FEV1/FVC before bronchodilator: 0.73; FeNO: 21 [ppb]; Peak expiratory flow: 330 L/min; Hemoglobin: 13 g/dL; White cell count: 7.1 10*3/uL; Blood eosinophils: 0.24 10*3/uL; Platelets: 255 10*3/uL; Potassium: 4.3 mmol/L; Creatinine: 0.96 mg/dL; eGFR (CKD-EPI 1943): 62 mL/min/1.73 m²; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Asthma Control Test: 13 at baseline, 22 at this visit **S**
- Hemoglobin: 12.9 g/dL at baseline, 13 g/dL at this visit **S**
- White cell count: 7.6 10*3/uL at baseline, 7.1 10*3/uL at this visit **S**
- Blood eosinophils: 0.42 10*3/uL at baseline, 0.24 10*3/uL at this visit **S**
- Platelets: 268 10*3/uL at baseline, 255 10*3/uL at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 0.92 mg/dL at baseline, 0.96 mg/dL at this visit **S**
- eGFR (CKD-EPI 1943): 66 mL/min/1.73 m² at baseline, 62 mL/min/1.73 m² at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 86.4 kg; blood pressure 128/78, pulse 72; oxygen saturation 97 percent |
| Respiratory | Clear; no wheeze on forced expiration |
| Mouth | No thrush |
| Extremities | No ankle edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Asthma, now well controlled** (J45.40). Well controlled (Asthma Control Test 22; FEV1 1.72 L, 85 percent predicted; FeNO 21 ppb) on the stepped-up maintenance dose, with good technique and adherence. She does not have severe asthma, because she is controlled on a medium dose of inhaled corticosteroid, so biologic therapy is not indicated; blood eosinophils today are 0.24 on inhaled steroid. One exacerbation needing prednisone this year is a risk factor, so she keeps a written plan and a low threshold to step up again. **S**
   - Step back down to one inhalation twice daily plus as needed, with the spacer.
   - Personal best peak flow set at 340 L/min; action plan zones confirmed.
   - Review in three months; repeat spirometry in a year.
2. **Moderate asthma exacerbation** (J45.41). Resolved; peak flow back to her best. **S**
   - Problem resolved.
3. **Hypertensive heart disease without heart failure** (I11.9). At target: clinic 128/78, home 126/76; potassium 4.3, eGFR 62. **S**
   - Continue amlodipine 5 mg.
4. **Gastro-esophageal reflux** (K21.9). Settled off omeprazole with meal timing. **S**
   - Omeprazole only if symptoms return.
5. **Obesity, class 1** (E66.811). Weight 86.4 kg, down 1.6 kg, as she has begun walking on the campus each morning now that her breathing allows it. **S**
   - Continue the walking plan; dietitian visit booked at her request.
   - She may return to the question of a medicine for weight at her next wellness visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 22; reliever about once a week; no night waking |
| Imaging | Spirometry after stabilization and peak flow | Three to six months after starting treatment; peak flow daily after an exacerbation | Completed today | FEV1 1.72 L (85 percent), FEV1/FVC 0.73; peak flow 330 L/min (personal best 340) |
| Imaging | FeNO to monitor response | To monitor anti-inflammatory therapy (NAEPP, conditional) | Completed today | 21 ppb, down from 46 |
| Laboratory | Blood eosinophils for the biologic assessment | At severe asthma assessment; repeat if low | Completed today | 0.24 on inhaled corticosteroid, six weeks after prednisone; white cells 7.1, hemoglobin 13.0, platelets 255 |
| Referral | Biologic assessment | When asthma is severe or uncontrolled despite optimized step 4 to 5 treatment | Not indicated | Not severe asthma: well controlled on medium-dose ICS-formoterol with good technique; to be revisited if control is lost or a second oral corticosteroid course is needed within a year |
| Self-management | Review after an exacerbation | Within one week of any exacerbation (CMID; GINA within one to seven days) | Deferred | Missed: after the exacerbation at the sick visit the nurse telephoned on days 2 and 7, but no in-person review was booked within a week. No harm resulted: she recovered fully and is well controlled today. Corrective action: the action plan and the clinic's exacerbation order set now book a visit within seven days automatically |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Correct with the spacer; few missed doses |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | One moderate exacerbation six weeks ago (one prednisone course this year); no emergency visit or admission |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | Stepped back down to low-dose maintenance and reliever |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Updated with her personal best of 340 L/min after the exacerbation |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Colds the main trigger; vaccines planned for the autumn |
| Referral | Pulmonary rehabilitation | For persistent breathlessness or deconditioning | Not indicated | No persistent breathlessness; walking daily |
| Examination | Blood pressure in clinic and at home | Every visit; home readings at diagnosis and after changes | Completed today | Clinic 128/78; home average 126/76: at target |
| Laboratory | Potassium and kidney function | Yearly, or after changes | Completed today | Potassium 4.3, creatinine 0.96, eGFR 62 |
| Survey | Depression screen | Yearly and as needed | Completed today | PHQ-2 0 |

## Goal progress

- A confirmed diagnosis within three weeks: spirometry with bronchodilator response, FeNO and an echocardiogram, with the pulmonology consultation. Outcome by 1948-03-23: Asthma confirmed by a 21 percent, 270 mL bronchodilator response and FeNO 46 ppb; heart failure excluded; hypertensive heart disease found, two weeks after the first visit. **S**
- Asthma Control Test 20 or more, no night waking, and travel to Washington without breathlessness. Outcome by 1948-07-27: Asthma Control Test 22; no night waking; travelled to two board meetings. **S**
- Correct inhaler technique with her own inhaler at every visit, and a written asthma action plan she can use. Outcome by 1948-05-04: Technique corrected with a spacer at six weeks; action plan written at diagnosis and used during the exacerbation. **S**
- Blood pressure below 130/80 at home and in clinic. Outcome by 1948-07-27: Clinic 128/78; home average 126/76 on amlodipine. **S**
- No exacerbation needing oral corticosteroids. Outcome by 1948-07-27: Not achieved: one moderate exacerbation with a cold, treated with five days of prednisone without admission. **S**

## Medication changes

- Stopped: Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: two inhalations twice daily and one as needed (stepped up during the exacerbation), no more than 12 inhalations a day **S**
- Started: Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: one inhalation twice daily and one as needed, no more than 12 inhalations a day **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026), Aether Forge
- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society

## Follow-up

- Asthma and blood pressure review in three months. Annual wellness visit in about two months, with influenza, COVID-19 and RSV vaccines. Follow the updated action plan. **S**
- Next scheduled visit 1948-09-21: subsequent annual wellness visit. **S**
